|Videos|February 11, 2022
Clinical Implications of BTK Inhibitors in CLL
Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
FDA Grants Orphan Drug Designation to Onvansertib for Chronic Myelomonocytic Leukemia
4
SBE303 Receives FDA Fast Track Designation in Pretreated Urothelial Cancer
5